SEARCH

SEARCH BY CITATION

References

  • 1
    Ramanathan S, Mathias AA, German P, et al. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet. 2011; 50(4):229244.
  • 2
    Lee JS, Calmy A, Andrieux-Meyer I, et al. Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings. HIV AIDS. 2012; 4:515.
  • 3
    Stribild® (elvitegravir 150 mg / cobicistat 150 mg / emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) tablets; Prescribing Information (United States). Gilead Sciences. Available at http://services.gileadhiv.com/stribild/pdf/pi. Last accessed October 23, 2013.
  • 4
    Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Recommendation on integrase inhibitor use in antiretroviral treatment-naive HIV-infected individuals from the HHS panel on antiretroviral guidelines for adults and adolescents. Rockville, MD: DHHS; [updated October 30, 2013]. Available at http://aidsinfo.nih.gov/contentfiles/upload/AdultARV_INSTIRecommendations.pdf. Last accessed October 31, 2013.
  • 5
    German P, Warren D, West S, et al. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr. 2010; 55(3):323329.
  • 6
    Ramanathan S, Custodio J, Gordi T, et al. Population pharmacokinetics of cobicistat-boosted elvitegravir in adult healthy subjects and HIV-infected patients. 13th International Workshop on Clinical Pharmacology of HIV Therapy, Barcelona, Spain, April 16–18, 2012. Conference Reports. Available at: http://www.natap.org/2012/pharm/Pharm_30.htm. Last accessed December 11, 2013.
  • 7
    German P, Warren D, Wei L, et al. Effect of food on pharmacokinetics of elvitegravir, emtricitabine, tenofovir DF and the pharmacoenhancer GS-9350 as a fixed-dose combination tablet. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, United States, September 12–15 2009. Abstract A1-1300.
  • 8
    Custodio JM, Yin X, Hepner M, et al. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection. J Clin Pharmacol. 2014; 54(4):378385.
  • 9
    Nakamichi N. A pharmacokinetic study of Viread® 300 mg tablet in healthy Japanese adult male volunteers. J New Rem Clin. 2005; 54(8):941948.
  • 10
    Furuie H, Nishino I, Matsuguma K, et al. A pharmacokinetic study of Truvada® tablet in Japanese healthy adult male volunteers. J New Rem Clin. 2006; 55(10):15151528.
  • 11
    Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004; 43(9):595612.
  • 12
    Droste JA, Kearney BP, Hekster YA, et al. Assessment of drug–drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. J Acquir Immune Defic Syndr. 2006; 41(1):3743.
  • 13
    Lepist EI, Phan TK, Roy A, et al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother. 2012; 56(10):54095413.
  • 14
    Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006; 50(10):32973304.
  • 15
    Zhu L, Liao S, Child M, et al. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study. J Antimicrob Chemother. 2012; 67(2):465468.
  • 16
    Agarwala S, Eley T, Villegas C, et al. Pharmacokinetic interaction between tenofovir and atazanavir coadministered with ritonavir in healthy subjects. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, Canada, April 28–30 2005. Abstract 16, Poster 2.9. Available at: http://img.medscape.com/pi/editorial/conferences/2005/4151/druginteract.pdf: Last accessed January 08, 2014.
  • 17
    Jullien V, Tréluyer JM, Rey E, et al. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother. 2005; 49(8):33613366.
  • 18
    Kearney BP, Mathias A, Mittan A, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006; 43(3):278283.
  • 19
    Hoetelmans RM, Mariën K, De Pauw M, et al. Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. Br J Clin Pharmacol. 2007; 64(5):655661.
  • 20
    DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr. 2006; 43(1):15.
  • 21
    Ramanathan S, Mathias A, Wei X, et al. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents. J Acquir Immune Defic Syndr. 2013; 64(1):4550.
  • 22
    DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012; 379(9835):24292438.
  • 23
    Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012; 379(9835):24392448.